0001628280-24-025886.txt : 20240530
0001628280-24-025886.hdr.sgml : 20240530
20240530174125
ACCESSION NUMBER: 0001628280-24-025886
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240528
FILED AS OF DATE: 20240530
DATE AS OF CHANGE: 20240530
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bonstein Sara
CENTRAL INDEX KEY: 0001604019
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30739
FILM NUMBER: 241006884
MAIL ADDRESS:
STREET 1: 305 COLLEGE ROAD EAST
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INSMED Inc
CENTRAL INDEX KEY: 0001104506
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 541972729
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 US HIGHWAY 202/206
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
BUSINESS PHONE: 908-977-9900
MAIL ADDRESS:
STREET 1: 700 US HIGHWAY 202/206
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: INSMED INC
DATE OF NAME CHANGE: 20000128
4
1
wk-form4_1717105276.xml
FORM 4
X0508
4
2024-05-28
0
0001104506
INSMED Inc
INSM
0001604019
Bonstein Sara
700 US HIGHWAY 202/206
BRIDGEWATER
NJ
08807
0
1
0
0
Chief Financial Officer
1
Common Stock
2024-05-28
4
M
0
3454
28.88
A
120935
D
Common Stock
2024-05-29
4
M
0
76731
28.88
A
197666
D
Common Stock
2024-05-28
4
M
0
3454
24.70
A
201120
D
Common Stock
2024-05-29
4
M
0
27074
24.70
A
228194
D
Common Stock
2024-05-28
4
M
0
3454
34.03
A
231648
D
Common Stock
2024-05-29
4
M
0
25046
34.03
A
256694
D
Common Stock
2024-05-28
4
M
0
3454
26.46
A
260148
D
Common Stock
2024-05-29
4
M
0
39446
26.46
A
299594
D
Common Stock
2024-05-28
4
M
0
3454
26.43
A
303048
D
Common Stock
2024-05-29
4
M
0
20111
26.43
A
323159
D
Common Stock
2024-05-28
4
M
0
3454
17.07
A
326613
D
Common Stock
2024-05-29
4
M
0
32156
17.07
A
358769
D
Common Stock
2024-05-28
4
S
0
20724
50.01
D
338045
D
Common Stock
2024-05-29
4
S
0
220564
50
D
117481
D
Stock Option (right to buy)
28.88
2024-05-28
4
M
0
3454
0
D
2030-02-03
Common Stock
3454
88186
D
Stock Option (right to buy)
28.88
2024-05-29
4
M
0
76731
0
D
2030-02-03
Common Stock
76731
11455
D
Stock Option (right to buy)
24.70
2024-05-28
4
M
0
3454
0
D
2030-05-12
Common Stock
3454
31436
D
Stock Option (right to buy)
24.70
2024-05-29
4
M
0
27074
0
D
2030-05-12
Common Stock
27074
4362
D
Stock Option (right to buy)
34.03
2024-05-28
4
M
0
3454
0
D
2031-01-07
Common Stock
3454
42146
D
Stock Option (right to buy)
34.03
2024-05-29
4
M
0
25046
0
D
2031-01-07
Common Stock
25046
17100
D
Stock Option (right to buy)
26.46
2024-05-28
4
M
0
3454
0
D
2031-05-12
Common Stock
3454
65186
D
Stock Option (right to buy)
26.46
2024-05-29
4
M
0
39446
0
D
2031-05-12
Common Stock
39446
25740
D
Stock Option (right to buy)
26.43
2024-05-28
4
M
0
3454
0
D
2032-01-06
Common Stock
3454
59386
D
Stock Option (right to buy)
26.43
2024-05-29
4
M
0
20111
0
D
2032-01-06
Common Stock
20111
39275
D
Stock Option (right to buy)
17.07
2024-05-28
4
M
0
3454
0
D
2032-05-11
Common Stock
3454
91506
D
Stock Option (right to buy)
17.07
2024-05-29
4
M
0
32156
0
D
2032-05-11
Common Stock
32156
59350
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
This is the weighted average sales price representing 20,724 shares sold at prices ranging from $50.00 to $50.07 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 220,564 shares sold at prices ranging from $50.00 to $50.08 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date.
/s/ Sara Bonstein, by Michael A. Smith as Attorney-in-fact
2024-05-30